Description
Key facts
Cell type:THP-1,
Species or organism:Human,
Tissue:Blood,
Knockout validation:Next Generation Sequencing,
Mutation description:Knockout achieved by CRISPR/Cas9; X = 1 bp deletion, 2 bp deletion; Frameshift: 99.99%,
Disease:Acute Monocytic Leukemia
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-FCGR1A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD64 also known as Fc gamma receptor 1a (FCGR1A) is a high-affinity receptor for the Fc region of immunoglobulin G (IgG). This receptor weighs approximately 72 kDa and is expressed on the surface of immune cells such as macrophages monocytes and activated neutrophils. CD64 protein plays an important role in immune responses by binding to antibodies and mediating processes such as phagocytosis and antibody-dependent cellular cytotoxicity (ADCC). Researchers often use anti-CD64 antibodies and CD64 markers to study its expression in various cellular contexts especially in flow cytometry.
Biological function summary
CD64 expression involves the binding of IgG which serves as a pivotal mechanism to facilitate phagocytosis and clearance of opsonized pathogens. CD64 does not operate solely; it is part of a larger receptor family that includes other Fc gamma receptors like CD16 and CD32. The regulation of CD64 differs from its relatives due to its higher affinity for IgG. This attribute enables CD64 to play a more significant role in triggering immune responses especially during infections and inflammatory processes.
Pathways
CD64 participates in the immune response pathway and is critical in the regulation of inflammatory responses. Key proteins interacting with CD64 in these pathways include the aforementioned CD16 and CD32 forming a network that ensures efficient immune system activation. The interaction with IgG and subsequent signal transduction underpin the receptor's functionality in these pathways harmonizing innate and adaptive immune responses.
CD64 expression correlates strongly with autoimmune disorders and inflammatory conditions. The receptor's role in orchestrating immune cell activation makes it relevant in diseases such as rheumatoid arthritis and sepsis. In rheumatoid arthritis CD64 interacts with immune complexes intensifying inflammation through enhancement of phagocytic activity. In sepsis increased CD64 marker expression on neutrophils can serve as a diagnostic indicator. Related proteins like CD16 and CD32 also participate in these disorders by modulating immune complex handling and cellular activation.
